(Q33397386)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

R Ramasubbaiah

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S M Perkins

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

J Schilder

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

C Whalen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

C S Johnson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

M Callahan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

T Jones

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

G Sutton

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

language of work or name

English

0 references

publication date

28 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

123

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

499-504

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

cites work

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Cancer: mutant ras proteins and cell transformation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

A human oncogene of the RAS superfamily unmasked by expression cDNA cloning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Point mutation of the ras oncogene in human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

BAY 43-9006: preclinical data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Some notable properties of the standard oncology Phase I design.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Weekly topotecan for recurrent platinum resistant ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

Compounds in clinical Phase III and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.08.033

10.1016/J.YGYNO.2011.08.033

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21955480%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference